Piperacillin/Tazobactam in Continuous Infusion versus Intermittent Infusion in Children with Febrile Neutropenia

Fortino Solórzano-Santos 1, Anaí Quezada-Herrera 2, Yazmín Fuentes-Pacheco 3, María G. Labra-Zamora 3, Genoveva Rodríguez-Coello 4, Carlos E. Aguirre-Morales 5, Dassaev Izelo-Flores 6, Onofre Muñoz-Hernández 7, and María G. Miranda-Novales 8

1Research Unit in Evidence-Based Medicine, Hospital Infantil De Mexico “Federico Gómez”, Mexico City; 2Hospital del Niño y del Adolescente Morelense, Morelos; 3High Specialty Medical Unit, Hospital de Pediatría, CMN SXXI, Instituto Mexicano del Seguro Social, Mexico City; 4Hospital para el Niño Poblano, Secretaría de Salud, Puebla de Zaragoza, Puebla; 5Centro Médico ABC, Mexico City; 6Hospital General de Zona No. 20, Instituto Mexicano del Seguro Social, Puebla; 7Research Directorate, Hospital Infantil de México “Federico Gómez”, SSA, Mexico City; 8Analysis and Synthesis of Evidence Research Unit, Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

ABSTRACT

Background: Febrile neutropenia (FN) is a common complication in children who receive chemotherapy for cancer. Objective: The objective of this study was to evaluate the clinical efficacy of the continuous versus intermittent infusion of piperacillin/tazobactam (TZP) in febrile neutropenic pediatric patients. Methods: This is a non-blinded randomized controlled clinical trial. Eligible group consisted of hemato-oncological patients with FN who were candidates to receive TZP. Patients were randomized to one of two groups: Group 1 received antibiotic treatment through intravenous intermittent infusion of TZP 300 mg/kg/day based on piperacillin, divided into four doses, not exceeding 16 g/day; Group 2 received an initial TZP loading dose of 75 mg/kg infusion over 30 min, and then a continuous infusion of TZP 300 mg/kg/day through central line with pump over 24 h. Results: There were 176 episodes that could be assessed, 100 in Group 1 and 76 in Group 2. There was no statistically significant difference in treatment failure in the experimental group (continuous infusion) compared with the intermittent group, 21% versus 13% (p = 0.15). The increase in the absolute risk reduction was 0.08% (95% confidence interval 0.12-0.30), and the number needed to treat was 12.4. One patient in each group died. Conclusions: There were no differences in fever resolution, clinical cure rate, or mortality when comparing the continuous with the intermittent TZP infusion. (REV INVEST CLIN. 2019;71:283-90)

Key words: Beta-lactams. Febrile neutropenia. Infusion. Piperacillin-tazobactam.

Corresponding author:
*María Guadalupe Miranda-Novales
Unidad de Investigación en Análisis y Síntesis de la Evidencia
Coordinación de Investigación en Salud
Instituto Mexicano del Seguro Social
Av. Cuauhtémoc, 330
Col. Doctores, Del. Cuauhtémoc
C.P. 06720, Mexico City, Mexico
E-mail: guadalumiranda@outlook.es

Received for publication: 10-12-2018

DOI: 10.24875/RIC.19002943
INTRODUCTION

Febrile neutropenia (FN) is a common complication in children who receive chemotherapy for cancer. Fever may be the only indicator of a severe infection and the prompt needs for antimicrobial treatment\(^1\). According to the current guidelines, initial empirical antimicrobial therapy should cover enteric Gram-negative microorganisms and *Pseudomonas aeruginosa*\(^2,3\); in special conditions, coverage for Gram-positive cocci should be included. Monotherapy with an anti-pseudomonas β-lactam, a carbapenem, or a fourth-generation cephalosporin has been recommended as the first-line therapy\(^3\). In pediatric oncology patients, infections by antibiotic-resistant *P. aeruginosa* are not common, although the clinical course can be devastating, and thus, some authors suggest antimicrobial combinations\(^4\). Increased prevalence of antimicrobial-resistant infections with Gram-negative bacteria has been reported in children, associated to a higher mortality rate\(^2\). Empirical antimicrobial treatment in these patients is based on different conditions such as clinical patient characteristics, local resistance patterns, and drug availability. It is of utmost importance that antibiotics achieve optimal tissue concentration in the pediatric population. It has been described that physiological changes in children with cancer in critical conditions can affect the pharmacokinetics of antibiotics, increasing the risk of failure to achieve adequate antimicrobial concentrations, and thus suppress the growth of resistant bacteria. Suboptimal antimicrobial dosing may be associated with poorer clinical outcomes\(^5\).

Piperacillin/tazobactam (TZP) is a beta-lactam/beta-lactamase inhibitor combination recommended as empirical treatment for pediatric FN patients. The β-lactam antibiotics are characterized by having a short elimination half-life, which conditions their administration schedule by brief intermittent infusions several times a day. For these antibiotics, a relationship exists between the killing of bacteria and the time that free drug concentration remains above the minimum inhibitory concentration (MIC) against a pathogen. Extending the duration of the infusion is one way to increase the free drug concentrations above the MIC, without using more drug per day. Extended or continuous infusion administration of TZP has been proposed to achieve the best inhibitory concentrations and obtain optimal pharmacodynamics exposures\(^6-8\). Due to the low number of circulating neutrophils in children with FN, they depend to a large extent on optimal bactericidal levels of antibiotics.

In our hospital, hemato-oncological patients with FN receive piperacillin/tazobactam monotherapy as empirical treatment since 2007. This treatment was selected due to the high frequency of extended-spectrum β-lactamase-producing (ESBL) enterobacteria, as a strategy to decrease the selective resistance pressure by ceftazidime and limit their persistence and spread. Considering the pharmacokinetic aspects described in children with cancer\(^6\), the objective of this study was to evaluate the clinical efficacy of the continuous infusion versus the intermittent administration of TZP in FN pediatric patients.

METHODS

A non-blinded randomized controlled clinical trial was conducted in a third-level pediatric hospital. The eligible group was hemato-oncological pediatric patients (≤ 17 years old), were presented at the hospital with an event of FN, and was candidates to receive empirical antimicrobial treatment with TZP. FN was defined as a single oral temperature of ≥ 38.3°C, or a temperature of ≥ 38.0°C sustained over 1 h and an absolute neutrophil count (ANC) < 500 cells/mm\(^3\), or an ANC that is expected to decrease to < 500 cells/mm\(^3\) over the next 48 h. The study period included from April 2012 to August 2015. Exclusion criteria: Chemotherapy-associated nephrotoxicity, suspected intravascular device-associated infections, a recent event (< 1 month) of methicillin-resistant *Staphylococcus aureus* or *Streptococcus pneumoniae* invasive infection, history of allergic reaction to any β-lactam, a FN episode 30 days before present admission, patients with severe sepsis or septic shock, and those in palliative care were excluded from the study. Elimination criteria: Chemotherapy-associated nephrotoxicity during the hospital stay while receiving antimicrobial treatment, violations of the protocol, patients with fungal or viral infections as a cause of fever, those with isolation of Gram-positive cocci or multiresistant Gram-negative bacilli, patients with localized infections (pneumonia, neutropenic colitis, skin and soft tissue infection, and anal fissures/perianal abscesses) that lead to changes in the antimicrobial
treatment in the first 72 h, and patients in the continuous infusion group in whom antibiotic infusion was suspended for more than 4 h.

The study was approved by the institutional ethical committee (number R-2012-3603-14), and informed consent was obtained from the study participants (parents or legal guardians). After parents signed the informed consent form and children the assent form, patients were allocated according to a computer-generated randomization list. Group 1 received antibiotic treatment through an intravenous intermittent infusion of TZP 300 mg/kg/day based on piperacillin, divided into four doses, not exceeding 16 g/day (diluted 50 mg/mL in 5% glucose solution over 30 min) and Group 2 received an initial TZP loading dose of 75 mg/kg infusion over 30 min (diluted 50 mg/mL in 5% glucose solution), and then a continuous infusion of TZP 300 mg/kg/day (diluted 25 mg/mL in 5% glucose solution) through central line with pump over 24 h. Before initiating the protocol, several sessions were conducted with the nursing staff to inform the study procedures. Preparation, administration schedule, and correct infusion rate in both treatment modalities were supervised.

Clinical evaluation was made at admission and every 24 h by two researchers (QHA and FPY). On hospital admission, each patient underwent hematic biometry, C-reactive protein (CRP), blood chemistry, and two peripheral blood cultures (taken from two different venipuncture sites, each 30 min apart) before starting antimicrobial treatment. Blood cultures were processed by BACTEC system (Becton-Dickinson). Growth bacteria and yeast were identified by the VI-TEK 2 system (bioMérieux).

FN episodes were classified as microbiologically documented infections (MDI), clinically documented infection, and fever of unknown origin (FUO). Outcomes: Clinical cure, when fever subsided within 96 h after starting antimicrobial treatment, or if clinical signs of infection resolved and the patient was discharged after completing the antimicrobial scheme. Treatment failure, if fever persisted and a modification of the initial empirical treatment was done, or if the patient died because of the infection. A protocol violation was defined as a modification of the empirical treatment without criteria for treatment failure.

Antibiotic regimens were adjusted according to microbiological culture results, when available, in consultation with an infectious diseases specialist.

**Statistical analysis**

Descriptive statistics with simple frequencies and percentages. Comparisons between groups were done with Mantel-Haenszel Chi-square, Fisher’s exact test, and Mann–Whitney U-test. Intention-to-treat analysis and per protocol were performed, as well as calculation of absolute risk reduction and number needed to treat. The sample size was calculated to detect a difference of 15% between the groups, alpha 0.5, beta 0.20, and power of 80%; at least 76 patients per group were needed.

**RESULTS**

During the study period (April 2012-August 2015), 327 events of FN were evaluated; 86 cases were excluded and 39 refused to participate. A total of 202 episodes were randomized: 112 were assigned to intermittent infusion (Group 1) and 90 to continuous infusion (Group 2). Twelve cases from Group 1 and 14 from Group 2 were eliminated. The causes for elimination were as follows: in Group 1, isolation of a Gram-positive microorganism and clinical infection that required extended antimicrobial coverage (four perianal abscesses and four pneumonias); in Group 2, the isolation of a resistant microorganism in five (two Gram-positive and three ESBL-producing enterobacteria), clinical infection that required extended antimicrobial coverage (two pneumonias and one neutropenic colitis), and five children without an adequate venous access and suspension of antimicrobial infusion for > 4 h, one with a documented viral infection (herpetic stomatitis), and one due to cisplatin-induced tubulopathy (Fig. 1).

There were 176 episodes of FN that could be evaluated, 100 in Group 1 and 76 in Group 2. The male gender was more frequent, 57.3% and 61.8% in each group. Median age was 9 and 10 years old (1-16 year) for Group 1 and Group 2, respectively. There were 34 (19.3%) episodes in patients with acute leukemia (24 acute lymphoblastic leukemia and 10 acute myeloblastic leukemia) and 142 (80.6%) with different neoplasias (solid tumors in 76, non-Hodgkin
lymphoma in 40, central nervous system tumors in 22, and malignant histiocytosis in 4). Disease distributions in groups were as follows: in Group 1, solid tumors were 83% and acute leukemia and lymphomas (non-Hodgkin and Burkitt type), 17%; in Group 2, solid tumors were 75% and leukemia and lymphomas (non-Hodgkin and Burkitt type) 25% (p = 0.20). There were no statistically significant differences in gender, age, type of cancer, comorbidity, neutrophil count and CRP values on admission, filgrastim administration, and intensity of fever (only 15% had > 39.1°C).

There were no statistically significant differences in clinical characteristics of FN episodes between groups (Table 1). There were 9% and 6.5% of MDI (bacteremia) in Group 1 and Group 2, respectively. Most of the episodes corresponded to FUO (81%). Fever decreased in the first 48 h after starting antibiotic therapy in 45% of patients. Improvement of signs and symptoms of infection at 72 h was similar in both groups (80% and 73%). There were 13 (13%) failures in Group 1 (six corresponded to MDI, five were clinically documented, and two were due to FUO), and 16 (21%) in Group 2 (four corresponded to MDI, eight to clinically documented, and four due to FUO). The difference was not statistically significant. One patient in each group died: in Group 1, one patient from septic shock due to Bacillus spp., and in Group 2, one patient with neutropenic enterocolitis (Table 2).
Enterobacteriaceae and other Gram-negative bacteria were the most frequent isolates (Table 3). All *P. aeruginosa* isolates were TZP susceptible, but in one patient (in the continuous infusion group), TZP was changed to a carbapenem due to fever persistence at day 4. In patients with ESBL-producing *Escherichia coli* and *Enterobacter cloacae* isolates, antimicrobial treatment was also changed to a carbapenem. In those patients with *Salmonella enteritidis* isolates, treatment was modified for cefotaxime.

With the failures in the experimental group (continuous infusion) and the intermittent group (21% vs. 13%), the increase in the absolute risk reduction was 0.08% (95% confidence interval [CI]: 0.03-0.19), and the number needed to treat was 12.4. In the intention-to-treat analysis, assuming that all patients lost or eliminated from the control and the experimental group had the same (acceptable) outcome, the absolute risk reduction was 0.06 (95% CI 0.04-0.177) and the number needed to treat was 16.4 patients.

**DISCUSSION**

Fever can be the expression of the beginning of a potentially severe infection in cancer patients receiving chemotherapy. An early diagnosis and initiation of the appropriate antimicrobial treatment could be
lifesaving. According to the current clinical guidelines, these patients need to receive empirical antimicrobial treatment, including an antipseudomonal β-lactam or a carbapenem3,4,6. TZP has been recommended as a suitable antibiotic in children9. With standard doses of β-lactams administered in intermittent infusion, a high peak concentration is attained, but a short half-life leads to a fall in plasma drug levels and suboptimal free drug concentration above the MIC (Ft > MIC) against certain pathogens. On the other hand, a prolonged (extended or continuous) antibiotic infusion offers more consistent plasma drug levels and maximizing of Ft > MIC6. Some studies using extended infusion TZP dosing strategies in adult population suggest best reaching of pharmacodynamic targets than with traditional intermittent dosing, and it has been associated with improved clinical outcomes7,10-12. There are fewer reports that explored this strategy in pediatric population; however, implementing extended infusion TZP as standard of care to pediatric patients is suggested to be achievable6,13,14.

In this study, we explored the efficacy of continuous TZP infusion in febrile neutropenic children, and we found that there were no differences in fever resolution, clinical cure rate, and mortality when comparing with intermittent infusion. Results of a recent study comparing extended infusion (4 h) of β-lactams versus bolus administration in FN found that extended infusion was superior (74% vs. 55%) in terms of overall response15. Most of the studies have not demonstrated statistically significant differences in clinical outcomes and mortality16,17, but several authors highlighted the reduction in costs18.

Limitations of this study include a low frequency of episodes with proven bacteremia (8%); some other studies in FN patients showed that this condition does not exceed 15%19. Results in this study are within the range of several reports. In this study, in about 45% of the cases, the fever decreased in the first 48 h of the start of the antibiotic treatment; some authors proposed a limit of 72 h to consider efficacy attributable to the antibiotic, although the average duration of fever is 3-4 days20. It is very likely that patients with fever lasting 24-36 h do not need antimicrobial treatment. Santolaya et al. have proposed to withhold antimicrobial treatment in children with cancer, fever, and neutropenia if a respiratory infection is present until a result of a polymerase chain reaction microarray for 17 respiratory viruses confirm a viral infection21; in our study, most of the patients had FUO. Some authors have ruled out the importance of the administration time for the first dose of antimicrobial in children with FN22. Until rapid and accurate microbiological diagnostic methods are available, cancer patients will continue to receive antimicrobial schemes for their safety. Despite having a higher frequency of P. aeruginosa bacteremia episodes in our study (one-third of the isolates), the outcome was not associated with death, contrary to 38.9% lethality in febrile neutropenic children and adolescents with P. aeruginosa bacteremia reported by Kim et al.4; furthermore, P. aeruginosa strains did not have a multidrug resistance profile.

Table 2. Type of infection and treatment outcomes of febrile neutropenia episodes

<table>
<thead>
<tr>
<th>Infections and outcome</th>
<th>Group 1 intermittent TZP infusion (n = 100)</th>
<th>Group 2 continuous TZP infusion (n = 76)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical diagnosis of infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbiologically documented</td>
<td>9</td>
<td>5</td>
<td>0.84</td>
</tr>
<tr>
<td>Clinically documented</td>
<td>7</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Fever of unknown origin</td>
<td>84</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Improvement at 72 h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>80</td>
<td>56</td>
<td>0.32</td>
</tr>
<tr>
<td>No</td>
<td>20</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Treatment failure</td>
<td>13</td>
<td>16</td>
<td>0.15</td>
</tr>
<tr>
<td>Deaths</td>
<td>1</td>
<td>1</td>
<td>0.67</td>
</tr>
</tbody>
</table>
Due to difficulties to ensure an adequate intravenous access in this study, four patients in the continuous infusions group were eliminated due to suspension of the infusion for \( \geq 4 \) h and were not included in the analysis, which may constitute a bias. This is one of the limitations of the continuous infusion strategy because a central venous catheter is needed to comply with it; other issues are that the mobility of the patient may be limited and that the administration of non-compatible IV medications could require placing an additional peripheral short catheter\(^{14,15}\). To ensure that this strategy is successful, a trained staff and the availability of a pump infusion system are required\(^{20}\). These issues could be resolved with an extended infusion administration (3–4 h).

In several studies, this modality proved to be safe and cost effective\(^{16-18}\). In this clinical trial, there was no difference in terms of improvement at 72 h or clinical cure. Results of the absolute risk reduction both in the analysis per protocol (patients who completed the treatment originally allocated), as well as in the intention-to-treat analysis, showed a small benefit in favor of the continuous infusion method. Prolonged infusion dosing strategies allow maintenance of antibiotic concentrations above the MIC against certain pathogens; this treatment modality is being used more frequently in critically ill and high-risk patients with FN. Until now, it is unclear whether prolonged infusions of \( \beta \)-lactams could translate into better clinical cure and/or survival. The accumulated information points to this being a good strategy. In addition, some studies found that prolonged infusion of TZP reduces the costs of treatment related to the form of administration and decreases dosing errors\(^{10,13-15,23,24}\).

In the present study there were no differences in fever resolution, clinical cure rate and mortality comparing the continuous with the intermittent infusion. Prolonged infusions of beta-lactam antibiotics warrant further evaluation in pediatric patients.

### Table 3. Microorganisms isolated from blood in febrile neutropenia episodes

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Group 1 intermittent infusion ((n=9))</th>
<th>Group 2 continuous infusion ((n=5))</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td><em>Klebsiella oxytoca</em></td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td><em>Salmonella enteritidis</em></td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Escherichia coli</em> ESBL+*</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><em>Enterobacter cloacae</em></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td><em>Klebsiella pneumoniae</em> ESBL+</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

*ESBL+: Extended-spectrum \( \beta \)-lactamase producer.

### REFERENCES


